enGenes Biotech reaches proof-of-concept for -exPAND bioreactor scale non-canonical amino acid incorporation process
News-ReleasesEnGenes Biotech GmbH
April 14th 2020
Vienna, Austria: – Recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) has reached successful proof-of-concept for bioreactor scale incorporation of non-canonical amino acid into antibody mimetic.
This proprietary -eXPAND process is scalable and delivers ~250 mg/L labeled antibody mimetic that can be selectively modified by dual labelling at a C-terminal cysteine and a non-canonical amino acid incorporated at a specific site.
Advanced bioconjugation solution
The -eXPAND project, commenced in 2018, was developed in collaboration with acib GmbH with funding from the Austrian Research Promotion Agency (FFG) in the BRIDGE program.
The -eXPAND approach allows, for example, labelling of an antibody fragment or affibody/nanobody with a drug payload and a fluorophore for detection and visualization. It is thus highly relevant for companies seeking solutions in the field drug development and bioconjugation.
For more information follow https://www.pharmaceutical-networking.com/engenes-biotech-xpand/
Comments